The MarketWatch News Section was not concerned in the development of this articles.
FOSTER City, Calif., Dec 22, 2020 (Globe NEWSWIRE through COMTEX) —
FOSTER Town, Calif., Dec. 22, 2020 (World NEWSWIRE) — Vaxcyte, Inc., formerly identified as SutroVax, a subsequent-era vaccine organization searching for to increase global well being by developing top-quality and novel vaccines built to protect against or take care of some of the most prevalent and deadly infectious health conditions around the globe, currently declared the marketing of Andrew Guggenhime from Main Economical Officer and Main Company Officer to President and Chief Money Officer helpful January 1, 2021. In this new position, Mr. Guggenhime will lead the finance, human resources, company communications, investor relations, business enterprise and corporate enhancement, strategy, details engineering and services activities at Vaxcyte.
“Andrew has shown his outstanding management capabilities because becoming a member of Vaxcyte previously this yr, and provides important practical experience across a vast array of capabilities,” reported Grant Pickering, Main Govt Officer and Co-founder of Vaxcyte. “Present-day announcement displays an evolution in our leadership structure which enables us to keep on to scale our group correctly as we execute on our mission and progress our pipeline of novel vaccine candidates, led by VAX-24, our pneumococcal conjugate vaccine candidate intended to protect against invasive pneumococcal sickness.”
Mr. Guggenhime joined Vaxcyte in May possibly 2020, bringing extra than two many years of finance, strategic and operational management working experience at both equally private and community healthcare firms. Mr. Guggenhime joined Vaxcyte from Dermira, Inc., the place he served as Main Monetary Officer from April 2014 as a result of the acquisition of the enterprise by Eli Lilly and Enterprise in February 2020. Prior to Dermira, Mr. Guggenhime served as Chief Economic Officer for CardioDx, Inc., a privately held professional-phase cardiovascular molecular diagnostics business. He also served as Main Fiscal Officer for Calistoga Pharmaceuticals, Inc., a privately held, growth-stage company, which was acquired by Gilead Sciences, Inc. in 2011, and as Main Economical Officer for Facet Biotech Corporation, a biotechnology firm that was obtained by Abbott Laboratories in April 2010. He beforehand served as Chief Money Officer of PDL BioPharma, Inc. till Facet Biotech was spun off from PDL BioPharma in December 2008. Prior to joining Facet Biotech, Mr. Guggenhime served as Chief Monetary Officer for Neoforma, Inc. a supplier of supply chain management answers for the healthcare marketplace, which was acquired by Worldwide Healthcare Trade, LLC in March 2006. Mr. Guggenhime started his vocation in fiscal companies at Merrill Lynch & Co. and Wells Fargo & Business. He now serves on the board of directors of Metacrine, Inc., a biotechnology business. Mr. Guggenhime retains an M.B.A. from the J.L. Kellogg Graduate Faculty of Administration at Northwestern College and a B.A. in worldwide politics and economics from Middlebury College or university.
Vaxcyte is a subsequent-generation vaccine company searching for to increase world overall health by creating top-quality and novel vaccines designed to avoid or treat some of the most typical and lethal infectious diseases around the world. The Company’s cell-free of charge protein synthesis platform, comprising the XpressCFTM system, exclusively accredited from Sutro Biopharma, Inc., collectively with Vaxcyte’s proprietary know-how, allows the style and design and output of protein carriers and antigens, the critical creating blocks of vaccines, in methods that the Firm believes standard vaccine technologies currently can’t. Vaxcyte’s guide vaccine prospect, VAX-24, is a preclinical, 24-valent wide-spectrum pneumococcal conjugate vaccine (PCV) being created for the avoidance of invasive pneumococcal sickness (IPD). Vaxcyte’s pipeline also consists of VAX-XP, a PCV with an expanded breadth of coverage of at the very least 30 strains, which include freshly emerging strains accountable for IPD and antibiotic resistance VAX-A1, a prophylactic vaccine applicant created to stop Group A Strep bacterial infections and VAX-PG, a therapeutic vaccine prospect created to sluggish or prevent the progression of periodontal disease by targeting the keystone pathogen accountable for this long-term, oral inflammatory disease. For extra data, go to www.vaxcyte.com.
Andrew Guggenhime, Main Monetary Officer & Chief Business enterprise Officer
(C) Copyright 2020 GlobeNewswire, Inc. All rights reserved.
The MarketWatch Information Section was not associated in the development of this material.